Clinical trials: Parkinson
Parkinson Disease
Influence of Pramipexole Extended Release on Medication Adherence in Parkinson´s Disease
This is an open-label, prospective post marketing surveillance study to be performed in Sweden. Only data of patients idiopathic PD should be documented, in whom the treating physician plans to initiate a pharmacotherapy with PPX…
- Trial name
- NCT01097421
- Testing
- Pramipexole Extended Release
- Volunteers
- 329 people
- Sponsor
- Boehringer Ingelheim
Parkinson's Disease
Exercise and Cognitive Training in Parkinson's Disease
This study compares the effects treadmill exercise, computerized cognitive training, or the combination of the two on executive function, dual-task performance, and performance on several Instrumental Activities of Daily Living…
- Trial name
- NCT01156714
- Testing
- Treadmill training with aerobic exercise, Memory training with computerized memory program, Combination of treadmill training and computerized memory
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- VA Office of Research and Development
Colorectal Carcinoma
Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)
In this study, participants with previously-treated locally-advanced unresectable or metastatic mismatched repair (MMR) deficient or microsatellite instability-high (MSI-H) colorectal carcinoma (CRC) will be treated with…
- Trial name
- NCT02460198
- Testing
- Pembrolizumab
- Volunteers
- 124 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson Disease
50 Hz Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Parkinson's Disease
Background: In transcranial magnetic stimulation (TMS), a device creates a short-lasting magnetic field which induces an electric current in the brain leading to a change in the activity of brain cells.
- Trial name
- NCT00977184
- Testing
- 50 HZ Repetitive TMS
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Carcinoma, Non-Small-Cell Lung, Melanoma
Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593)
This study has been designed to evaluate the safety of pembrolizumab in participants in India with unresectable or metastatic melanoma and participants with non-small cell lung cancer (NSCLC) who are either untreated (programmed…
- Trial name
- NCT03715205
- Testing
- Pembrolizumab
- Where
- 8 sites in India
- Volunteers
- 150 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson's Disease, Gait Impairment
Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease
The purpose of this research study is to examine whether Methylphenidate (MPD) can result in improvement of gait (walking) in a population of Parkinson's Disease (PD) patients whose main disability is freezing of gait.
- Trial name
- NCT00526630
- Testing
- Methylphenidate (MPD)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Cincinnati
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)
This is a study of pembrolizumab (MK-3475) for advanced gastric or gastroesophageal junction adenocarcinoma; pembrolizumab will be given as monotherapy to participants who have had previous treatment or who are treatment-naïve…
- Trial name
- NCT02335411
- Testing
- pembrolizumab, cisplatin, 5-FU
- Volunteers
- 318 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson's Disease
Pioglitazone in Early Parkinson's Disease
This is a multi-center, double-blind, placebo controlled clinical trial of two dosages of oral pioglitazone (15 milligram(mg) and 45 milligram (mg)) for safety, tolerability, and futility.
- Trial name
- NCT01280123
- Testing
- Pioglitazone
- Where
- 38 sites in United States
- Volunteers
- 210 people
- Sponsor
- University of Rochester
Parkinson Disease
Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)
This is a double blind, placebo-controlled clinical trial of 15 months duration designed to examine early Mirapex (pramipexole) treatment vs. delayed Mirapex (pramipexole) treatment in patients with new onset Parkinsons disease
- Trial name
- NCT00321854
- Testing
- pramipexole
- Where
- 99 sites in United States, Austria and 8 more
- Volunteers
- 535 people
- Sponsor
- Boehringer Ingelheim
Parkinson's Disease, Levodopa Induced Dyskinesias (LID)
Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID.
This study was terminated early due to slow enrollment with 87 of 162 planned subjects enrolled. The purpose of this multi-center, randomized, double-blind, parallel-group, 16 week study is to compare the efficacy and safety of…
- Trial name
- ALLAY-LID-I (NCT02153645)
- Testing
- 240mg Amantadine HCl ER tablets, 320mg Amantadine HCl ER tablets
- Where
- 56 sites in United States, Canada and 3 more
- Volunteers
- 87 people
- Sponsor
- Adamas Pharmaceuticals, Inc.
Parkinson Disease, Deep Brain Stimulation
The Impact of Exercise on Subthalamic Nucleus Neural Activity in Parkinson's Disease
Fifteen PwPD who have undergone DBS surgery and utilize the Percept system will complete a FE and VE exercise session on a stationary cycle while Off antiparkinsonian medication.
- Trial name
- NCT05905302
- Testing
- Forced and Voluntary Exercise
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Jay Alberts
Parkinson Disease
Use of a Non-Invasive Brainstem Neuromodulation Device to Improve Neurovascular Status in Parkinson's Disease
This study is a single-site, double-blinded, randomized clinical trial designed to elucidate mechanism(s) of action for symptomatic benefits observed in Parkinson's disease (PD)
- Trial name
- NCT04598828
- Testing
- Non-invasive brainstem stimulation
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Wake Forest University Health Sciences
Parkinson Disease
Exercise and Parkinson's: Comparing Interventions and Exploring Neural Mechanisms
Parkinson disease (PD) is characterized by substantial disability and reduced quality of life, both of which can be attributed in large part to difficulties with walking.
- Trial name
- NCT01768832
- Testing
- Treadmill, Tango, Stretching
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- Washington University School of Medicine
Colorectal Cancer
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study
The purpose of this China extension study is to assess the safety and efficacy of coformulated favezelimab/pembrolizumab (MK-4280A) in adult Chinese participants with metastatic colorectal cancer.
- Trial name
- NCT05600309
- Testing
- favezelimab/pembrolizumab, regorafenib, TAS-102
- Where
- 24 sites in China
- Volunteers
- 94 people
- Sponsor
- Merck Sharp & Dohme LLC
Nonsquamous Non-small Cell Lung Cancer
Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study
The purpose of this study is to assess the safety and efficacy of pemetrexed+platinum chemotherapy+pembrolizumab (MK-3475) with or without lenvatinib (MK-7902/E7080) as first-line intervention in adults from mainland China with…
- Trial name
- NCT04716933
- Testing
- Pembrolizumab, Carboplatin, Cisplatin
- Where
- 19 sites in China
- Volunteers
- 201 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson's Disease
A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease
This multicenter, randomized, double-blind, placebo-controlled, Phase 2 study will evaluate the efficacy of intravenous prasinezumab (RO7046015/PRX002) versus placebo over 52 weeks in participants with early Parkinson's Disease…
- Trial name
- PASADENA (NCT03100149)
- Testing
- RO7046015
- Where
- 55 sites in United States, Austria and 3 more
- Volunteers
- 316 people
- Sponsor
- Hoffmann-La Roche
Parkinson Disease
First Presentation of Parkinson Disease Patients to Neurologist
In this study information is gathered about the treatment of Parkinson patients who present themselves in a neurological practice for the first time
- Trial name
- NCT00802178
- Where
- 311 sites in Croatia, Czechia and 7 more
- Volunteers
- 2,448 people
- Sponsor
- Boehringer Ingelheim
Parkinson
Effects of Transcranial Pulse Stimulation in Parkinson's Disease
The investigators are studying if Transcranial Pulse Stimulation (TPS) can improve various symptoms, including movement problems, thinking abilities, mood, fatigue, freezing while walking, voice quality, and issues with smell and…
- Trial name
- NCT06676995
- Testing
- Transcranial Pulse Stimulation (TPS)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Spaulding Rehabilitation Hospital
Parkinson's Disease
A Pilot Study of Oxaloacetate in Subjects With Treated PD
The purpose of this study is to determine if Oxaloacetate (OAA) is a safe and effective treatment for Parkinson's disease. Each subject will be asked to make 3 study visits and complete two safety follow-up phone calls over a 4…
- Trial name
- NCT01741701
- Testing
- Oxaloacetate (OAA)
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Kansas Medical Center
UC (Urothelial Cancer)
Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab + epacadostat vs pembrolizumab + placebo as a treatment for recurrent or progressive metastatic urothelial carcinoma in patients who have failed a…
- Trial name
- NCT03374488
- Testing
- Pembrolizumab, Epacadostat
- Where
- 135 sites in United States, Australia and 16 more
- Volunteers
- 84 people
- Sponsor
- Incyte Corporation